The first phase trial of the COVID-19 vaccine in China has yielded good results. The vaccine has helped volunteers between the ages of 18 and 59 make antibodies. The Chinese COVID vaccine (CoronaVac) is safe, according to a report in The Lancet, the world’s oldest and best-known medical journal. ‘CoronaVac’ has been added to the list of safe vaccines in the trial phase.
The vaccine was reported for being tested on the bodies of around 600 volunteers in between April and May 2020. The vaccine is working well in each of their bodies and it is also safe. One of the most common side effects is a pain in the injection area. The two lowest dose injections were given to everyone at 14-day intervals. That is why antibodies have been made in everyone’s body.
The report further states that the effects of CoronaVac have been shown to produce antibodies in the body. But those who have once recovered from a corona infection have produced light antibodies than their immunities. However, scientists hope that the vaccine will be able to prevent coronavirus.
Studies have shown that the effects of the vaccine increase significantly after two injections at 14-day intervals. The researchers said that the 3 mg injection is the most effective in terms of side effects. The study was conducted at the Jiangsu Provincial Center for Disease Control and Prevention in Nanjing, China. Fenchai Zhu, the Head of the research team, told that it clearly indicated that the vaccine would have its effect within four weeks.
Fenchai Zhu also told that this vaccine can be used in case of emergency. He also told that in case of long-term effects, i.e. if the risk of Coronavirus was low, the two injections would be given at one-month intervals thereby achieving much greater result. It means, if two injections are given at one-month intervals instead of 14 days, its effect on making antibodies will be much greater. However, research is still needed to determine how long the vaccine will maintain its effectiveness.
CoronaVac is made by separating the virus from the body of a person infected with coronavirus in China. The vaccine has since been tested in Suining County in Jiangsu Province of China. However, Johns Hopkins University researcher Naor Bar-Zeev told about the trial that scientists should be equally vigilant even after the third stage trial and after getting the vaccination license.